pharmaceuticals

Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study

Eli Lilly and Co. (NYSE: LLY) announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the Fifth Annual Maui Derm NP+PA Fall meeting. ...
Read Full Story »

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Johnson & Johnson (NYSE: JNJ) surprised investors on Wednesday morning by announcing a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial. While this in and ...
Read Full Story »

FDA Accepts for Review the Newest Treatment for C Diff

Merck & Co. Inc. (NYSE: MRK) has just announced that the U.S. Food and Drug Administration (FDA) accepted a couple New Drug Applications (NDAs) for review. Specifically, the FDA accepted ...
Read Full Story »

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April. Even the biggest and ...
Read Full Story »

Major Duchenne Muscular Dystrophy Trial Is Ready to Launch

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment is for the Phase 3 PolarisDMD trial ...
Read Full Story »

Are Dova Pharma Investors Getting the Most Out of This Acquisition?

Dova Pharmaceuticals Inc. (NASDAQ: DOVA) shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. Through this acquisition, Sobi is looking ...
Read Full Story »

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

With the final quarter of 2019 beginning next Tuesday, many investors are taking a long hard look at their portfolios and trying to make some adjustments. While the end of ...
Read Full Story »

Good News for Teens Suffering Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib in patients aged 12 and older with moderate to severe atopic dermatitis ...
Read Full Story »

Is This Trial Really Disappointing News for Non-Alcoholic Steatohepatitis Sufferers?

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) shares dropped on Thursday after the company announced topline results from its Argon-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH). ...
Read Full Story »

Achillion Pharma Wins Big With FDA Breakthrough

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for danicopan (ACH-4471) in combination with a C5 monoclonal antibody ...
Read Full Story »

Why This Cardiopulmonary Trial Is a Big Hit

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares jumped on Wednesday after the firm announced results from its midstage trial focused on novel therapies for cardiopulmonary orphan diseases. Specifically, the data is ...
Read Full Story »

Short Sellers Grow More Selective in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Parkinson’s Patients Should Be Optimistic About Acadia’s Study

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for ...
Read Full Story »

Why This Late-Stage Narcolepsy Study Is Way Ahead of Schedule

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) shares jumped on Monday morning after the firm announced that the U.S. Food and Drug Administration (FDA) has agreed to the company’s proposed amendments to ...
Read Full Story »

Are Alder Shareholders Getting Enough in the Buyout?

Alder BioPharmaceuticals Inc. (NASDAQ: ALDR) shares skyrocketed on Monday after the firm announced that Lundbeck would acquire it. The transaction is valued at up to $1.95 billion net of cash ...
Read Full Story »